色婷婷综合成人av_99久久精品国产毛片_成人一区二区在线_国产91丝袜在线播放_久久人人爽人人爽人人片av免费_欧美伊人

上海非利加實業(yè)有限公司Logo

熱門詞: 進(jìn)口電動溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進(jìn)口電動溫度調(diào)節(jié)閥數(shù)據(jù)表進(jìn)口電動高溫調(diào)節(jié)閥-德國進(jìn)口電動高溫法蘭調(diào)節(jié)閥進(jìn)口電動蒸汽調(diào)節(jié)閥-德國進(jìn)口電動蒸汽調(diào)節(jié)閥

當(dāng)前位置: 首頁 > 所有品牌 > Arena
Arena
Arena Arena

Arena Pharmaceuticals  
Arena制藥公司是一家生物制藥公司發(fā)現(xiàn),開發(fā)和商品化的藥物,在治療領(lǐng)域的心血管疾病,中樞神經(jīng)系統(tǒng),炎癥和代謝性疾病的重點。該公司正在開發(fā)一種化合物,這種行為稱為G蛋白偶聯(lián)受體的藥物靶標(biāo),使用其專利技術(shù),其中包括組成物激活受體技術(shù)和黑色素的管道。競技場的產(chǎn)品包括APD811,第二階段的臨床試驗5-HT2C5 - 羥色胺受體激動劑,其將被用于治療肥胖和APD334,I期臨床試驗的產(chǎn)品,用于治療失眠,使用。其研究和發(fā)展計劃還包括APD597,APD916,APD791和APD125,所有這一切都是口頭的候選藥物。該公司始建于1997年4月由Dominic P.貝安和杰克·利夫和總部設(shè)在加利福尼亞州圣迭戈。

Our Focus
We are a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, or GPCRs, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.
Our Research & Development Pipeline
Lorcaserin is our most advanced investigational drug candidate and is intended for weight management, including weight loss and maintenance of weight loss. In October 2010, the US Food and Drug Administration, or FDA, issued a Complete Response Letter, or CRL, with respect to the lorcaserin New Drug Application, or NDA, we submitted in December 2009. In the CRL, the FDA stated that it completed its review of the NDA and determined that it could not approve the application in its then present form.
After completing various studies, analyses and other activities in response to the lorcaserin CRL, in December 2011, we resubmitted the lorcaserin NDA. The FDA accepted the resubmission for filing and review and assigned a new Prescription Drug User Fee Act, or PDUFA, target date of June 27, 2012.
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee met on May 10, 2012, to discuss the lorcaserin NDA. The advisory committee voted 18 to 4, with one abstention, that the available data demonstrate that the potential benefits of lorcaserin outweigh the potential risks when used long-term in a population of overweight and obese individuals.
We are also seeking regulatory approval for lorcaserin in the European Union. On March 2, 2012, we filed a marketing authorization application, or MAA, for lorcaserin through the centralized procedure with the European Medicines Agency, or EMA, and the EMA subsequently accepted the filing. The acceptance of the MAA filing begins the EMA’s review process.
In addition to lorcaserin, our prioritized earlier-stage programs include APD811, an internally discovered, orally available agonist of the prostacyclin receptor intended for the treatment of pulmonary arterial hypertension; APD334, an internally discovered, orally available agonist of the S1P1 receptor intended for the treatment of a number of conditions related to autoimmune diseases, including multiple sclerosis; APD371, an internally discovered, orally available agonist of the cannabinoid receptor 2 intended for the treatment of pain; and GPR119 agonists, intended for the treatment of type 2 diabetes. Our internally discovered, oral drug candidates also include temanogrel, which was formerly called APD791 and is intended for the treatment of arterial thrombosis and other related conditions, and nelotanserin, which we previously studied for insomnia and was formerly called APD125.
Our Strategy
The key elements of our general strategy are as follows:
Focus on lorcaserin. We intend to focus our efforts on seeking approval for lorcaserin in the United States, the European Union and other select markets outside of the United States. Pending regulatory approvals, we intend to commercialize lorcaserin in the United States under our marketing and supply agreement with Eisai and in other markets with one or more collaborators or independently.
Selectively advance our other lead candidates. We intend to selectively advance our pipeline of drug candidates independently or through licensing, collaborations or other opportunities.
Maintain research and development capabilities to advance our pipeline. Our technologies, our drug discovery infrastructure and the integrated approach to research used by our scientists have allowed us to identify and develop a number of GPCR targets and novel compounds, and our development infrastructure has allowed us to develop compounds through NDA filing. We expect that our research and development capabilities will continue to play an important role in the support of the further development and potential commercialization of lorcaserin. We intend to maintain our research and development capabilities to selectively advance our programs and to discover additional drug candidates.

關(guān)于我們客戶服務(wù)產(chǎn)品分類法律聲明
主站蜘蛛池模板: 精品国产乱码久久久久久丨区2区 | 久久精品国产99国产精2020新增功能 | 国产精品久久久久无码av | 羞羞的视频 | 欧美午夜精品久久久久久浪潮 | 亚洲精久久 | 亚洲国产二区 | 色综久久 | 波多野结衣先锋影音 | 免费黄色成人 | 国产成人一级毛片 | 久久久久久久久久久久99 | 欧美久久久网站 | www国产在线观看 | 蜜桃传媒一区二区 | 国产色| 日韩国产欧美视频 | av中文字幕在线观看 | 欧美日视频 | 日韩欧美在线不卡 | 日韩高清一区二区 | 久久久久久91| 国产成人久久 | 久久久久久91 | 国产精品美女久久久久久久网站 | 99福利视频| 综合婷婷| 偷拍自拍第一页 | 欧美午夜精品久久久久久人妖 | 日韩欧美一级 | 九九色综合| 欧美视频区 | 日韩免费一区 | 亚洲成av人片在线观看无码 | 国产色视频 | 高清国产一区二区三区 | 日韩av一区在线 | 天天操综合网 | 免费网站色 | 免费一级毛片免费播放 | 国产一区二区久久久 |